Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Diseas...
Alpha Tau Medical Ltd. - Ordinary Shares (DRTS)
Company Research
Source: GlobeNewswire
JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients. The IDE supplement allows the Company to include an additional cohort for locally advanced pancreatic cancer patients, and to increase the number of each cohort to 15 patients, for a total of 30 patients across the two cohorts, at up to 10 U.S. clinical trial sites. Alpha Tau CEO Uzi Sofer commented, “Following the incredible data that we released las
Show less
Read more
Impact Snapshot
Event Time:
DRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DRTS alerts
High impacting Alpha Tau Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
DRTS
News
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewswire
- Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State UniversityGlobeNewswire
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI SymposiumGlobeNewswire
DRTS
Earnings
- 11/20/25 - Beat
DRTS
Sec Filings
- 12/18/25 - Form 6-K
- 12/11/25 - Form 144
- 12/9/25 - Form 6-K
- DRTS's page on the SEC website